Login to Your Account

Wilex Shares Plunge; Rencarex Disappoints in Phase III Study

By Cormac Sheridan
Staff Writer

Wednesday, October 17, 2012
Shares in Wilex AG plunged 60 percent just before the markets closed in Frankfurt, Germany, Tuesday, on news that a protracted Phase III trial of Rencarex (girentuximab) failed to meet the primary endpoint of disease-free survival in patients with clear cell renal carcinoma (ccRCC).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription